IXICO today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors (‘wearable biosensors’) in a Phase II clinical trial for a neurological disorder.
This is IXICO’s first commercial agreement using activity sensors to evaluate exploratory digital measures in early phase clinical research and follows a presentation of IXICO’s approach to measuring sleep disturbances at the “Mobile devices for clinical trials in neurological diseases workshop” earlier this year at the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD) meetings.
IXICO, the digital technologies company serving neuroscience, today announces that it has signed a new contract with a customer for its technology enabled imaging services. The contract value is US$690k over a two and a half year [...]
IXICO to provide specialist MR and PET imaging services in Phase II Huntington’s disease clinical trial
IXICO today announces that it has signed a new contract with a North American based biopharmaceutical company. The contract value is £1.2m over a three year term. IXICO will provide its technology enabled imaging services in [...]
IXICO announces an expansion of its pilot of the Assessa® PML platform which includes Biogen, a leading company in Multiple Sclerosis (“MS”), and expert reading institutions. The Assessa® PML digital platform is being piloted in five [...]
IXICO is today holding an Expert Symposium on the impact and future of imaging and digital biomarkers in Alzheimer’s disease. The symposium is set to coincide with the Alzheimer’s Association International Conference (AAIC) in London, UK. [...]
IXICO today announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a Phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease [...]
Strong revenue growth Delivering on contracts and commercial collaborations IXICO announces its unaudited interim results for the six months ended 31 March 2017. Financial Highlights Improved gross profit margin performance of 56% (2016: 49%) EBITDA loss [...]